Moxonidine in Patients Undergoing Vascular Surgery

University Hospital Basel

Status and phase: Terminated; Phase 3

Conditions: Cardiac Disease; Vascular Surgery

Treatments: Drug: moxonidine

Study type: Interventional

Funder types: Other

Identifiers

NCT00244504

158/01

Details and patient eligibility

About

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Enrollment: 141 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• abdominal aortic or peripheral vascular surgery

Exclusion criteria

• unstable angina,
• severe symptomatic heart failure (NYHA IV)
• systolic blood pressure at rest < 100 mmHg
• bradycardia (<50/min)
• higher grade AV heart block
• creatinine clearance < 30 ml/min
• pregnancy
• no consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

141 participants in 2 patient groups, including a placebo group

I

Active Comparator group

Description:

moxonidine group

Treatment:

Drug: moxonidine

II

Placebo Comparator group

Description:

placebo group

Treatment:

Drug: moxonidine